Pfizer Settles $345M EpiPen Consumers Suit, But Viatris Marches On
Executive Summary
After four years of litigation, Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan establish a monopoly for the EpiPen autoinjector device.
You may also be interested in...
Robert Califf Nominated To Retake FDA Commissioner Role
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face if confirmed to a second stint as the nation's top medtech regulator.
Medtech And US DoJ: EpiPen, Dermagraft Lead 2017 Payouts To Feds
US DoJ collected more than $1bn in penalties from device manufacturers this year, chiefly on false claims and manufacturing violations. Here is a roundup and sortable table of the payouts.
‘Imminent’ Gilenya ANDA Launches Halted By US Supreme Court
In a dramatic twist, Gilenya ANDA sponsors are now unable to launch their generic products in the US after the US Supreme Court intervened in favor of originator Novartis, superseding the US Federal Circuit.